• Adenosine injection (with Chinese trademark欧达乐^®) was approved for marketing.
• Nasdaq-listed company Lantheus acquired Cerveau, a joint venture of Sinotau.
• Closed a CNY ¥1.1bn financing round and the total financing amounts to CNY ¥2.6bn.
• Florbetaben F 18 injection（with Chinese trademark 欧韦宁^® and foreign trademark Neuraceq^® was received regulatory approval from National Medical Products Administration (NMPA) in China, which is the first domestic radiopharmaceutical targeting β-amyloid approved to be used to support diagnosis of Alzheimer’s disease (AD).